UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.
For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.
Insomnia and Sleeplessness (IRB-SBS #2017-0089-00)
Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness (SHUTiOASIS) (NCT03213132)
Primary Investigator: Lee Ritterband
Clinical Research Coordinators: Christina Frederick, Kirsten MacDonnell
Gastrointestinal Oncology (IRB-HSR #20326)
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Primary Investigator: Matthew Reilley
Clinical Research Coordinator: Susan Jones
Renal Cell Carcinoma (IRB-HSR #20331)
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC) (NCT02996110)
Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Jennifer Drake
Acute Myeloid Leukemia ( IRB-HSR #20410)
A Phase III, Double-blind, Placebo-controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients 18 Years or Older With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy -PRAN-16-52
Primary Investigator: Michael Keng
Clinical Research Coordinator: Amelia Hodson
Idiopathic Parkinson’s Disease (IRB-HSR #180001)
A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System (NCT03319485)
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Idiopathic Parkinson’s Disease (IRB-HSR #17552)
A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Chronic Trigeminal Neuropathic Pain (IRB-HSR #170004)
A Feasibility Study of Focused Ultrasound to Perform Bilateral Medial Thalamotomy for the Treatment of Chronic Trigeminal Neuropathic Pain (NCT03309813)
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Newly Diagnosed Glioblastoma (IRB-HSR #19800)
INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT). (NCT02977780)
Primary Investigator: David Schiff
Clinical Research Coordinator: Starlene Truslow
Newly Diagnosed Glioblastoma (IRB-HSR #20105)
A Phase I Study Targeting Newly Diagnosed Glioblastoma with anti-CD3 x anti-EGFR Bispecific Antibody Armed T cells (EGFR BATs) in Combination with Radiation and Temozolomide (NCT03344250)
Primary Investigator: Camilo Fadul
Clinical Research Coordinator: Melissa Otoya
Newly Diagnosed & Recurrent Glioblastoma (IRB-HSR #170002)
A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma (NCT03150862)
Primary Investigator: David Schiff
Clinical Research Coordinator: Carol Woodburn
Recurrent Glioblastoma or Anaplastic Astrocytoma (IRB-HSR #18471)
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma (NCT02414165)
Primary Investigator: David Schiff
Clinical Research Coordinator: Starlene Truslow
Recurrent IDH1-R132X Mutant Advanced Solid Tumors (IRB-HSR #170009)
An Open-Label, Non-Randomized, Multi-center Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY 1436032 and to Characterize its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-Tumor Activity in Patients with IDH1-R132X Mutant Advanced Solid Tumors. (NCT02746081)
Primary Investigator: David Schiff
Clinical Research Coordinator: Carol Woodburn
Hematologic Malignancies (IRB-HSR #20241)
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma as Front Line Therapy
Primary Investigator: Craig Portell
Clinical Research Coordinator: Amelia Hodson
Gastrointestinal Oncology (IRB-HSR #20415)
Phase 2 Randomized Study of Atezolizumab in Combination with Cobimetinib Versus Atezolizumab Monotherapy in Participants with Cholangiocarcinoma (NCT03201458)
Primary Investigator: Paul Kunk
Clinical Research Coordinator: Susan Jones
Genitourinary Oncology (IRB-HSR #20262)
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma
Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Jennifer Drake
Genitourinary Oncology (IRB-HSR #2032)
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (NCT03012321)
Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Julio Torres
Thoracic Oncology (IRB-HSR #20474)
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671). (NCT03425643)
Primary Investigator: Ryan Gentzler
Clinical Research Coordinator: Maria Davenport
